The update of CheckMate 067 clinical trial for advanced melanoma at 6.5-year follow-up reported an OS of 72.1 months in patients treated with combination anti-programmed cell death protein 1 (anti-PD-1) nivolumab with cytotoxic T-cell lymphocyte-antigen 4 (CTLA4) ipilimumab and 36.9 months in patients treated with single-agent nivolumab [5]. The gene discussed is PDCD1; the disease is melanoma.